Lung Cancer Clinical Trial
— VM4-037Official title:
An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
Verified date | March 2010 |
Source | Siemens Molecular Imaging |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Phase: Exploratory Study
Objectives: To collect drug bio-distribution data, begin collection of baseline and
tumor/background imaging data, acquire experience to improve study design and the conduct of
future studies
Design: Exploratory, open label, nonrandomized, multi-center study
Duration: Three visits - one screening, one imaging, and one follow-up visit at 24 hours
post-dose
Procedures: Informed consent, collection of demographic information and medical history,
physical examinations, vital signs, 12-lead ECGs, routine blood tests to assess major organ
functions, complete blood counts and clinical chemistries for safety, blood sample for CA-IX
assay, pre-dose and post-dose blood samples for metabolite analysis, dosing with
[F-18]VM4-037, PET imaging scan, dosimetry estimation (normals), urine collections
(normals), tumor immunohistochemistry with CA-IX biomarker, follow up to imaging to collect
adverse events
Subjects: Approximately sixteen (16) adult subjects including four (4) healthy volunteers
and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head &
neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
Status | Completed |
Enrollment | 16 |
Est. completion date | March 2010 |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Normal Volunteers - Subject is = 18 years old at the time of investigational product administration, and subject is male or female of any race / ethnicity - Subject or subject's legally acceptable representative provides written informed consent - Subject is capable of complying with study procedures - Subject is capable of communicating with study personnel - Subject must have renal and hepatic functions and haematological values as defined by laboratory results within defined ranges Cancer Subjects - Subject is = 18 years old at the time of the investigational product administration, and subject is a male or female of any race/ethnicity - Subject or subject's legally acceptable representative provides written informed consent - Subject is capable of complying with study procedures - Subject is capable of communicating with study personnel - Subject must have renal and hepatic functions and haematological values as defined by laboratory results within defined ranges - Subject must have confirmed or highly suspected non-small cell lung cancer (local or with metastases), squamous cell carcinoma (advanced stages) of the head and neck whose primary origin was from oral cavity, oropharynx, hypopharynx or larynx (local or with metastases), large solitary hepatic carcinoma (primary or metastatic), or renal cell carcinoma (local or with metastases ) - Subject has an adequate size of tumors (=2 cm) that should be amenable to imaging and biopsy for immunohistochemistry assay using CA-IX and/or hypoxia biomarkers - Subject did not have any anticancer treatment intervention between [F-18]VM4-037 scan and sampling of biopsied tissue - Subject is scheduled for a clinical [F-18]FDG PET scan within 14 days either prior to or after the investigational, [F-18]VM4-037 scan (with no anticancer treatment interventions between the two PET scans) - Subject has a value of = 60% at the time screening according to the Karnofsky Performance Status Scale Exclusion Criteria: Normal Volunteers - Subject is < 18 years old at the time of investigational product administration - Subject is nursing - Female subject is pregnant - Subject is unable to remain still for duration of imaging procedure - Subject has a significant hepatic or renal disease as defined by previous medical history or abnormal renal and hepatic functions determined by above lab tests in inclusion criteria - Subject has previously received [F-18]VM4-037 at any time - Subject has been involved in an investigative, radioactive research procedure within the past 14 days - Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data or data quality - Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives Cancer Subjects - Subject is < 18 years old at the time of investigational product administration - Subject is nursing - Female subject is pregnant - Subject is unable to remain still for duration of imaging procedure - Subject has significant hepatic or renal disease as defined by previous medical history or abnormal renal and hepatic functions determined by above lab tests in inclusion criteria - Subject has previously received [F-18]VM4-037 at any time - Subject has been involved in an investigative, radioactive research procedure within the past 14 days - Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data or data quality - Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives - Subject has had an anticancer treatment intervention between [F-18]VM4-037 scan and biopsied tissue sampling - Subject has had an anticancer treatment intervention between [F-18]VM4-037 scan and [F-18]FDG scan - Subject has an inadequate tumor sites or volume (< 2 cm) to allow for PET images and biopsy for immunohistochemistry |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Siemens Molecular Imaging |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug. | (3) study visits, including the initial screening visit, the imaging visit, and the 24 hour follow-up visit | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|